Clinical Trials

How difficult is it to develop a new drug? Statistics have the answer

The EMA says it will review its standards for first-in-human trials

Cell therapy successes are widely hailed as breakthroughs, but will adverse effects and patient deaths hold the field back?

Particle agglomeration can compromise the clinical efficacy of pharmaceutical products and must therefore be closely controlled. This article provides practical guidance on using automated imaging for efficient agglomerate detection.

OMNISEC measures the Critical Quality Attributes of polymeric pharmaceutical excipients with unrivalled sensitivity supporting their efficient use to formulate safe and effective pharmaceutical products.

Angus Dalgleish tells us about his experience with EU regulation – and why he thinks Britain should leave the EU.

Sitting Down With... Ann Hayes, Owner, The Ann Hayes Consultancy, Stevenage, UK.

The pressure for increased efficiency pervades the pharma industry, including the clinical trials sector, where traditional supply models can lead to overstocking, waste and higher costs. Is there a more effective supply strategy?

Sitting Down With... Christian Schneider, Director of the National Institute for Biological Standards and Control (NIBSC), UK.

Statisticians are vital in the pharma industry, but rarely do they receive public fanfare for their work. The Award for Statistical Excellence in the Pharmaceutical Industry aims to change the status quo.